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Perspectives in Treatment 
Resistance   & Bipolar 
depression.
Amresh Srivastava
Treatment-resistant depression (TRD) 
is a major public health problem
Learning objectives
Clinical 
characteristics of 
treatment 
resistance
Methods to treat  
TRD & Evidence of 
their efficacy
Outcome & Treatment resistance 
Confronting Clinical issues.
Disability 
Quality of life
Suicide
Underdiagnosed
Under-treated
Causes, neurobiology &  
managem nt of ‘Treatment-
Resistance’
WHAT IS THE NATURE & 
CHARACTERISTICS OF 
TREATMENT RESISTANCE?

Resistance to What??
Measuring TRD: Staging Treatment Resistance
Stage I Inadequate response to 1 monotherapy
Stage II Inadequate response to 2 adequate monotherapy 
trials (different classes)
Stage III Stage II resistance plus inadequate response to 1 
augmentation trial
Stage IV Stage III resistance plus inadequate response to a 
second augmentation trial
Stage V Stage IV resistance plus inadequate response to 
bilateral ECT
Adapted from: Thase ME, Rush AJ. J Clin Psychiatry. 1998;59(suppl 5):5
Souery D et al. Eur Neuropsychopharmacol. 1999;9:83
TRD: chronic, recurrent, debilitating 
Trivedi MH, Lin EH, Katon WJ. Consensus recommendations for improving adherence, self-management, and 
outcomes in patients with depression.CNS Spectr. 2007 Aug;12(8 Suppl 13):1-27
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Lifetime Prevalance Receive Treatment Tx as per guideline
Non-response 
Wijeratne C, Sachdev P.Treatment-resistant depression: critique of current approaches.Aust N Z J Psychiatry. 2008 
Sep;42(9):751-62.
Nonremission is Common
Depression in Primary Care, Vol. 2. Treatment of Major Depression. Rockville, MD: US Dept. of 
Health and Human Services, AHCPR Publication No. 93-0550, 1993.
Definitions of Response and Remission
% Reduction in Score
Remission >75%
Response 50% - 74%
Partial Response 25% - 49%
Nonresponse <25%
TRD >40%1
The causes of TRD are not fully 
understood.
1.Taylor SM: Electroconvulsive therapy, brain-derived neurotrophic factor, and possible neurorestorative benefit of the clinical
application of electroconvulsive therapy. J ECT. 2008 Jun;24(2):160-5.
2. Nemeroff CB Prevalence and management of treatment-resistant depression.J Clin Psychiatry. 2007;68 Suppl 8:17-25 
12 months Prevalence rate 2 3%- Stage 1
2% - stage 2..
Paradigms Which Contribute to Faulty TRD Labeling
Parker et al 2005, J of Affect Dis Machado-Vieira R, Soares JC.Treatment-resistant mood disorders  Rev Bras Psiquiatr. 2007 Oct;29 Suppl 
2:S48-54
CAN IT BE 
IDENTIFIED?
Predictors of Non-Response
IS THERE A SUBGROUP?
CLINICAL…OR 
BIOLOGICAL??
Biology : 
No specific neurobiology TRD.
Exploring newer brain targets
• NT: Dopamine, NMDA,
• Aminoacids : glutamate/glutamine/GABA cycling1
• Neuronal nitric oxide synthisase factor ( NOS) via Serotonine 
signaling2
• Neuropeptides  P/ Y3
• Endogenous modulators
• Beta 3 – adrenoreceptos ( agonist: amibegrone)
• Nicotinic receptors
1.Price B, et al Biological psychiatry, 2008 Dec
2.Ulak G, Pharmacol. Biochem behav.2008.
3.Nikisch G, Eur.Psychiatry.2008.23:356-9
Biological Changes in treatment Resistant Depression
Biology1, 2
1.Taylor SMElectroconvulsive therapy, brain-derived neurotrophic factor, and possible neurorestorative benefit of the clinical application of electroconvulsive 
therapy.J ECT. 2008 Jun;24(2):160-5
2. Kitamura Y, Gomita Y. [Development of animal models of treatment-resistant depression in rats] Nihon Shinkei Seishin Yakurigaku Zasshi. 2008 
Apr;28(2):93-100
3. Wijeratne C, Sachdev P.  Treatment-resistant depression: critique of current approaches. Aust N Z J Psychiatry. 2008 Sep;42(9):751-62.
4.Maeng S, Zarate CA Jr. . The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular 
mechanism underlying its antidepressant effects. Curr Psychiatry Rep. 2007 Dec;9(6):467-74.
5.Penttila J et al , J Psychiatry neurosci. 2009; 34(2):127-35 
N-methyl-D-aspartate (NMDA) receptor 4
Decreased Neurogenesis
Reduced global cortical folding5
HOW TO CONFIRM 
TREATMENT 
RESISTANCE?
Decision tree for TRD
Diagnosing treatment resistance
Was 
compliance 
adequate?
Y
Was dosage 
adequate?
Y Was the 
duration of 
Tx adequate
Y
Was anything 
interfering with 
drug-kinetics?
Y
Was the 
diagnosis 
correct
Y
Was the 
assessment 
comprehensive
Stress
Physical 
illness
Substance
Psychosis
Polarity
1.Depressed Mood
2. Suicide ideation or attempt
Organic 
Depression
TRD - Common Diagnosis
No manic or hypo 
manic feature
Depression within 
personality disorder
Focus on ‘symptoms constellation ’
exclusion of physical & psychiatric conditions
Differentiate treatment resistance 
from features of chronicity.
Towards a Comprehensive assessment of 
Depressive disorder.
Outcome
…….
What clinical conditions 
may present as treatment 
resistant depression?
WHAT CLINICAL CONDITIONS  
CAN PRESENT AS TREATMENT 
RESISTANT DEPRESSION?
Bipolar Disorder is a 
Multidimensional Illness
Subsyndromal
mania (hypomania) 
Mania
Depression
Mania
Remission
Subsyndromal
depression
Vieta E, et al. Bipolar Disord 2005; 7 Suppl 4:21-33.
Lifelong management of this lifelong illness involves 
targeting all phases of the disorder – atypical antipsychotics 
can play a major role
Bipolar II Depression
• Bipolar II disorder is a common disorder, 
• prevalence of approximately 3-5%. 
• Distinct clinical features
• The key to diagnosis - recognition of past 
hypomania, 
• This is responsible for a significant rate of 
missed diagnosis, 
• It is unclear if bipolar II disorder is over-
represented in TRD 
Bipolar II disorder: a review.
Berk M, Dodd S.
Bipolar Disord. 2005 Feb;7(1):11-21.
MISSED MANIA
BIPOLAR SPECTRUM
DISORDER
Bipolar diathesis for TRD
Manic symptoms 
during depressive 
episodes in 1,380 
patients with bipolar 
disorder: findings 
from the STEP-BD.
Goldberg JF, Perlis 
RH, Bowden 
CL, Thase 
ME, Miklowitz 
DJ, Marangell 
LB, Calabrese 
JR, Nierenberg 
AA, Sachs GS.
Am J Psychiatry. 
2009 Feb;166(2):173-
81
Impact of Bipolar Disorder on Patients’ Lives
Healthy life Reduced by 12 years
Working life Reduced by 14 years
Life expectancy Reduced by 9 years
Employment problems Twice as common
Divorce / separation Twice as common
Onset is usually during late adolescence and early adulthood, a time at which individuals 
are establishing their careers and building long-term relationships
Results for patients developing bipolar disorder in their mid-20s
Coryell et al 1993; Scott 1995
Atypical depression
• 70% of depression with atypical features met with DSM IV criteria for 
bipolar II 
• 60% had antecedents cyclothymic & hyperthymic temperament
• Interpersonal sensitivity & atypical features were found to be powerful 
prospective predictors of bipolar II 
Anxious – bipolar co morbidity
The evolving bipolar spectrum 
• Prototype I,II ,III & IV 
• Bipolar I – full-blown mania
• Bipolar 1 & ½ : depression with protected hippomania
• Bipolar II : depression with  hippomania
Outcome status:
What happens when TRD is treated?
• Not very encouraging.
• Nine outcome studies, Total N = 1279; follow-up duration - 1 
to  10 years.
• In the short term, TRD was highly recurrent 
• as many as 80% of those requiring multiple treatments 
relapsing within a year of achieving remission. 
• For those with a more protracted illness, the probability of 
recovery within 10 years was about 40%. 
• TRD was also associated with poorer quality of life and 
increased mortality. 
Fekadu A,et al  What happens to patients with treatment-resistant depression? 
A systematic review of medium to long term outcome studies Affect Disord. 2008 Nov 11.
How do we treat the  
Treatment 
resistance??
& what is the outcome?
Current (or future) 
Treatment Options 2,3
2.Carvalho AF, Cavalcante JL, Castelo MS, Lima MC.Augmentation strategies for treatment-resistant depression: a literature review.J Clin Pharm 
Ther. 2007 Oct;32(5):415-28
3.. Tadić A, Lieb K.  [Pharmacological therapy for therapy-resistant depression. New developments] Nervenarzt. 2007 Nov;78 Suppl 3:551-63;
(STAR*D)1 50% of "real world” -
MDD fail to achieve 
remission, even after four 
carefully monitored sequenced 
treatments. 
1.Kennedy SH, Giacobbe P,Treatment resistant depression--advances in somatic therapies.Ann Clin Psychiatry. 2007 Oct-Dec;19(4):279-87.
Antidepressants:
SSRI, TCA
MAOI, SNRI & others
..Safety & efficacy of
antidepressants
1.Optimization
inadequate dose & inadequate duration
• Only 11 percent of patients receive adequate therapeutic therapy. 
• Inadequate therapy - particularly prevalent in elderly patients.
• The clinician need to maximize the dosage or duration of therapy. 
• Higher than recommended dosage: some patients benefit 
• An adequate duration has been defined by some - four to six weeks.  --
six weeks –10-12 weeks -- to elicit a full ADD response. 
Papakostas GI,et al  A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, 
with selective serotonin reuptake inhibitors for the treatment of major depressive disorder.
Eur Neuropsychopharmacol. 2008 Feb;18(2):122-7
Have the cytochrome P450 (CYP450) genotyping test
Selecting right ADD
.
Selectivity Ratios for Uptake Inhibitor 
Antidepressants 
(measured in vitro)
10000 1000 100 10 0 10 100 1000 10000
5 – HT selectivity NA selectivity
Selectivity ratio
Understanding 
the Illness
The way 
Forward
Switch to another ADD?  Which…??
• 1 in 4 patients on SSRI’s  have a  
response on 2nd drug:
– Bupropion-SR
– Sertraline
– Venlafaxine-XR
• Within class
• 1st SSRI may be ineffective/ 
intolerable
• 2nd SSRI may be effective/ tolerable
• Out-of-class
• SSRI  ----> TCA = 30 to 50%
four 
clinical trials
(n = 1496)
non-SSRI 
antidepressant 
(bupropion, 
mirtazapine, 
venlafaxine)
SSRI
Pooled remission 
rates 28% 
(for non-SSRIs)
Pooled remission rate
23.5%
Papakostas GI et al Treatment of SSRI-resistant depression: 
a meta-analysis comparing within- versus across-class switches 
Biol Psychiatry. 2008 Apr 1;63(7):699-704.
3/18/09
3. Combination Therapy 1
• Combination therapy involves the addition of a second antidepressant 
agent to the therapeutic regimen. 
• Concurrent administration of two or more antidepressant agents 
(e.g., adding trazodone [Desyrel], desipramine [Norpramine] or bupropion 
[Wellbutrin] to fluoxetine) may result in a different therapeutic response 
than that produced by use of either drug alone. 
• However, no double-blind, placebo-controlled studies recommend the 
usefulness of this practice.
• In addition, this approach does not allow for adequate evaluation of 
monotherapy and may lead to significant adverse effects or drug-drug 
interactions
1.Berlim MT, Fleck MP, Turecki G.Current trends in the assessment and somatic treatment of resistant/refractory major 
depression: an overview.Ann Med. 2008;40(2):149-59

4.Augmentation Therapy1
• Involves adding a second agent, but one that is not routinely regarded as 
an antidepressant.2
• Dopaminergic agents, 7
• atypical antipsychotics, 7
•
Psychostimulants, benzodiaze
pines/hypnotics, hormones 
and
• Anticonvulsants. 7
• Testosterone 1
• Foliate 3
• Omega 34
• Lamotregene5
• Olanzapine/fluoxetine6
1.Amiaz R, Seidman SN.Testosterone and depression in meCurr Opin Endocrinol Diabetes Obes. 2008 Jun;15(3):278-83.
2. Wijeratne C, Sachdev P.  Treatment-resistant depression: critique of current approaches. Aust N Z J Psychiatry. 2008 Sep;42(9):751-62
3. Morris DW, Trivedi MH, Rush AJ. Folate and unipolar depression. J Altern Complement Med. 2008 Apr;14(3):277-85.
4.Owen C, Rees AM, Parker G The role of fatty acids in the development and treatment of mood disorders. Curr Opin Psychiatry. 2008 Jan;21(1):19-24.
5.McIntyre J, Moral MA. Spotlight on lamotrigine for depression.Drug News Perspect. 2006 Sep;19(7):427-30
6. Dodd S, Berk M.  Olanzapine/fluoxetine combination for treatment-resistant depression: efficacy and clinical utility. Expert Rev Neurother. 2008 
Sep;8(9):1299-306
7. Carvalho AF, et al Augmentation strategies for treatment-resistant depression: a literature review . J Clin Pharm Ther. 2007 Oct;32(5):415-28
Shall I persist, increase or add?
Licht & Qvitzau 2002
100mgs Sertraline
Progress
Amitriptyline and clomipramine 
are more effective than SSRIs   
(but more side effects and more 
toxic in overdose)
The difference is that these drugs 
affect both serotonin (5HT) and 
noradrenaline
Other drugs that have a similar effect 
are:
Venlafaxine
Mirtazepine
Duloxetine
Are these also more effective?  
Crucial 
questions
Combining and Switching
Crucial 
questions
4a.Lithium. 
Low dose 
• Enhances serotonin transmission 
• Reduces  activity of post-synaptic  5-HT receptors. 
• Increases serotonin levels in the synaptic cleft. 
• Response rates of 30 to 65%
• within 48 hours to 3-6 weeks
• Most research support
• Least used
• Start at 150 mg
• Sr. level 0.4 to 0.8 mEq/L
• Aim for lower serum level 
 The thyroid hormone triiodothyronine (T3)  appears to be a 
more effective than tetraiodothyronine (T4 ) 
 Effective in small dosages; for example, 25 to 50 µg per day. 
 T3 may be used to augment response to TCA, MAOI,  and SSRIs.
 effective in  50 to 6%0 patients.
 Monitoring thyroid function
 T3 potentiates noradrenergic activity, 
 Its mechanism of action is not clearly understood.
 Relatively safe, few AE – allergic  x 2-3 weeks 
4b.Thyroid hormone: Low dose, short- term
4c.Pindolol. 
• The 5-HT1A postsynaptic antagonist
• Accelerates the onset of action of ADD  by 
preventing negative feedback to the 
presynaptic 5-HT1A receptor. - higher 
levels of serotonin in synapse. 
• At dosages of 2.5 to 7.5 mg/D x 6 weeks, 
• AE   - < 10%
4d.Buspirone. 
• Anxiolytic. 
• No specific/intrinsic antidepressant effects.  
• Dosages of 15 to 30 mg /D x 3 Months : 
improved response – 2/3rd of patients.
• Full agonist at the presynaptic autoreceptor 
and  partial agonist at the postsynaptic 
autoreceptor. 
• Decreases extracellular serotonin 
concentrations over the short term.
. 
4e.Pramipexole
• Large effect size (0.6-1.1):
• With a low switching in bipolar 
patients (1% mania, 5% hypomania). 
• The pooled discontinuation rate - 9%.
• Neuroprotective 
• Effects on sleep architecture.
• SE in Parkinson’s disease
• Sleep attacks, 
• Compulsive behaviors 
• Pathologic gambling, 
• Restless legs syndrome;  
• Psychosis
• Aiken CB.Pramipexole in psychiatry: a systematic review of the 
literature.J Clin  Psychiatry. 2007 Aug;68(8):1230-6.
• Lamotregene 
• Carbamezapine
4f.Anticonvulsants
• Triple Reuptake Inhibitors 
(TRI)
• Target all three of brain’s monoamines
(serotonin, norepinephrine, dopamine)
• Expected on the market by 2010
• Better efficacy and tolerability, faster 
acting, less side effects, treats broader range of 
symptoms
4g.Novel Antipsychotics
1- combination ( OFC) 2- Switch to AATPD
 SDA, beneficial 
 50% Response
 25% Remission
 Olanzapine 1
 According to results, 
Aripiprazole, Olanzapine, and 
Risperidone are reasonable 
choices as augmentation agents
 With only aripiprazole currently 
having an FDA( USA)  indication 
for this use.2
1. Selis MA, Peeters FP. Augmentation with atypical antipsychotics for the treatment of patients with a therapy-resistant depression: a 
review] Tijdschr Psychiatr. 2008;50(4):213-22
2. Philip NS, Carpenter LL, Tyrka AR, Price LH. Augmentation of antidepressants with atypical antipsychotics: a review of the current 
literature. J Psychiatr Pract. 2008 Jan;14(1):34-44
Clozapine in medication- and electroconvulsive 
therapy-resistant, depressed inpatients: a case series 
• Quante A, J Clin Psychopharmacol. 2007 Dec;27(6):715-7.  
Summary of the Evidence Base for the Efficacy 
of Atypical Antipsychotics in Bipolar Disorder
Acute Treatment Maintenance / Continuation Treatment
Mania Depression Mania Depression
Quetiapine ++ ++ ++ ++
Olanzapine ++ + ++ +
Risperidone ++ ? ++ +?
Aripiprazole ++ – ++ –
Ziprasidone ++ ? ? ?
Asenapine ++ ? ? ?
Paliperidone ++ ? ? ?
++ = at least one good RCT showing clinically significant effects
+ = at least one RCT showing some effect
- = RCT evidence of a lack of clinically significant effects
? = uncertain or no controlled data available
Health Canada Approved Indications for Agents Used in the 
Treatment of Bipolar Disorder
Acute Bipolar 
Depression Acute Mania
Maintenance 
Treatment
Agents
ATYPICALS
Clozapine 
Olanzapine √ √*
Quetiapine (SEROQUEL XR) √ √
Risperidone √
Paliperidone 
Ziprasidone 
OTHER
Carbamazepine √ √+
Divalproex √
Lamotrigine 
Lithium √ √
+ for use after treatment failure on traditional mood stabilizer
*See PM.  Evaluation from 2 “time to relapse” trials with manic or 
mixed index episode
This chart does not imply comparable efficacy or 
safety profiles.
All brand names and product names used in this slide 
are trade names, service marks, trademarks, or 
registered trademarks of their respective owners.
Rapid cycling
(n=393)
Non-rapid cycling
(n=1,814)
****** ******
LSM 
change  
from 
baseline 
to Week 8
*** p<0.001 vs placebo ITT, LOCF
Baseline values: Rapid cycling - quetiapine 300 mg, 29.4; 600 mg, 29.5; 
placebo, 29.9
Non-rapid-cycling - quetiapine 300 mg, 28.7; 600 mg, 28.3; placebo, 28.9
Im
pr
ov
em
en
t
Quetiapine 600 mg
Quetiapine 300 mg
Placebo
BOLDER & EMBOLDEN (acute phase):
Change in MADRS Total Score
BOLDER I & BOLDER II:MADRS Items at Week 8
At Week 
1, significant 
improvement 
was seen in 
6 out of 10 
items‡
Percentage Improvement at Week 8 ITT, MMRM** 
Combined 
Studies
‡ §
¶
‡ §
‡ §
‡ §
‡ §
‡ §
§
§
§
* Montgomery-Asberg Depression Rating Scale.
† Data combined from two 8-week, multicenter, randomized, double–blind, placebo-controlled, monotherapy bipolar 
depression trials.
P < 0.05 vs placebo at Week 1    § P < 0.001 vs placebo at Week 8 ¶ P < 0.05 vs placebo at Week 8. 
Data on File, DA-SER-45.
How do we explain?
Why do Atypical antipsychotics have Antidepressant action?
A: Regional distribution of   5-HT System in the Brain?? 
Depression in schizophrenia : perspective in era of ‘atypical antipsychotics’. Siris ,S.G.AJP 2000 ;157
ECT
• ECT in TRD
• average 14.6 months in 
their current episodes 
• 6.2 years of their lifetime in 
depression.
• Failed to respond to an 
average of 5.4 different ADD  
• (65.8%) responded 
• (53.3%) achieved remission 
.
– Khalid N The effectiveness of electroconvulsive 
therapy in treatment-resistant depression: a 
naturalistic study. J ECT. 2008 Jun;24(2):141-5.
• The acute effect is well 
established
– Continuation Tx is required
– In 1 study, within 24 weeks of 
achieving remission, 64% 
relapsed.1
– TRD is predictive of post-ECT 
relapse
• TRD patients at high risk for 
relapse: only 32% 
maintained response in next 
12 months2
1. Sackeim et al, JAMA,2001;285:1299-1307.
2. Prudic J, et al Biol.Psychiatry,2004;55:301-312.
Deep Brain Stimulation (DBS): 
The Surgical option
• FDA approved for Parkinson’s & 
tremors
• Investigational for OCD TRD
• Stereotactic target from MRI
• Two chest wall internal pulse 
generator
• Burr hole in skull for electrode 
placement
• Stimulation parameter 
programmed by computer 
through a ‘WAND’
• ive potential targets – ide tified 
:
• Ventral striatum/nucleus 
accumbens,
• Subgenual cingulate cortex (area 
25), 
• Inferior thalamic peduncle, 
• Rostral cingulate cortex (area 
24a), and 
• Lateral habenula. 
Hauptman JS, DeSalles AA, Espinoza R, Sedrak M, Ishida W.Potential surgical targets for 
deep brain stimulation in treatment-resistant depression.Neurosurg Focus. 2008;25(1):E3
Deep Brain stimulation 
• Reduced activity in this region (shown in blue at bottom) is seen with six months of chronic deep 
brain stimulation.
• This reduction correlates with the antidepressant effect of the treatment. 
• (Images courtesy of Helen Mayberg)
• www.dana.org/uploadedImages/Images/Spotlight_Images/Cerebrum_DBS_2008-03_spot.jpg
Efficacy: [Subcallosal cingulate 
gyrus ] for treatment-resistant 
depression 
• There were both early and 
progressive benefits to DBS. One 
month after surgery, 
• 35% - response
• 10%- remission. 
• Six months after surgery, 
• 60% -responders
• 35% -remission, 
• Benefits maintained at 12 months. 
rTMS
• No general anesthesia
• Outpatient procedure
• Lower energy requirement. 
• "the magnetic field can be highly focused, 
• No social stigma
• Specific targeted stimulation
• No convulsion requirement 
• Minimal side effects such as mild headache 
and discomfort at the site of stimulation
• No known adverse effects on cognition
• Potential advantages - as an add-on
• The long term effectiveness of rTMS for 
severe depression is unknown.
• The use, if any, of continued maintenance 
therapy is unknown.
• Long term pragmatic patient outcomes such 
as time to further treatment,
TMS add-on on escitalopram 
TRD with 2 failed
trial of ADD
GR II- 15 sessions
TMS+ 
20 mg ESCT
Gr !- Sham 15 sessions
TMS
+ 20 mg ESCT
Follow up of 3 weeks
Outcome assessment by HAM-D 
shows effects size of  0.7
For 3 
weeks
duration
Bretlau LG et al Repetitive transcranial magnetic stimulation (rTMS) in combination with escitalopram in patients with treatment-resistant major
depression: a double-blind, randomised, sham-controlled trial.
Pharmacopsychiatry. 2008 Mar;41(2):41-7
Vegus Nerve 
stimulation ( VNS)
• Well tolerated
• A safe and feasible procedure, despite 
its limitations
• Acts via innervation of the nucleus 
tractus solitarius, with secondary 
projections to limbic and cortical 
structures that are involved in mood 
regulation 
• Efficacy data not randomized
• Surgical procedure
• Non-acute antidepressant effect
• MRI contraindication
• Battery 
1.Daban C, et al Safety and efficacy of Vagus Nerve Stimulation in treatment-resistant depression. A systematic review. J Affect Disord. 2008 
Sep;110(1-2):1-15
2.Nemeroff CBVNS therapy in treatment-resistant depression: clinical evidence and putative neurobiological mechanisms. 
Neuropsychopharmacology. 2006 Jul;31(7):1345-55.
Preventing treatment resistance
Treating treatment resistance
